Business Wire

CA-MULTEFIRE-ALLIANCE

22.6.2021 14:02:13 CEST | Business Wire | Press release

Share
MulteFire Alliance (MFA) Simplifies Path to 5G Private Network Deployment for Enterprise

MFA (MulteFire® Alliance), an international organization dedicated to enabling industry verticals to deploy private cellular networks globally, today announced its expanded mission to enable 5G private networks in unlicensed, shared and locally licensed spectrum by providing guidance to enterprises seeking to deploy their own network.

Leveraging existing 3GPP 5G specifications, MFA will deliver Uni5G Technology Blueprints to industry verticals. These blueprints will help enterprises select and implement the key features from the 3GPP standards that are relevant to their specific deployment. MFA will also develop best practices and deployment guides, including industry resources on understanding all available spectrum options for 5G private networks. The first Uni5G Technology Blueprint will be available in Q4 2021.

According to a recent industry report by ABI Research , the total addressable market size for 5G and 4G/LTE private network equipment for Industry 4.0 use cases will reach ~$35B by 2030.

“MFA paved the way for industries to contemplate how they can deploy their own private network in unlicensed spectrum using MulteFire 4G/LTE-based cellular technology with high-performance, built-in security and mobility benefits,” said Mazen Chmaytelli, president, MFA. “Now through our expanded role in enabling 5G private networks, MFA will provide industry verticals with practical guidance on deployment that will meet their unique requirements and determine which spectrum option is right for their site.”

MFA provides a unique global PLMN ID for 5G and MulteFire private networks to industry verticals

MFA has been awarded a global Public Land Mobile Network (PLMN) ID by the ITU. MFA is planning to make this PLMN ID available to industry verticals. The PLMN ID is a series of numbers that identifies a specific network and ensures that only authorized devices connect to that network.

With access to a unique global PLMN ID number, industry verticals are able to deploy their own 5G private network in locally licensed spectrum or a MulteFire private network in unlicensed spectrum today.

MFA members and others under MFA authorization are able to bundle the PLMN ID with their network equipment, thus simplifying the deployment process for enterprises by eliminating the need for them to separately apply for a PLMN ID.

“Across all industry verticals, we’re witnessing a drive to increase control, reliability and security through deployment of private networks,” said Chmaytelli. “Enterprises can now leverage locally licensed spectrum using Uni5G technology, and later can use global unlicensed or shared spectrum when 5G NR-U solutions become available. Through our Uni5G Technology Blueprints and our unique global PLMN ID, MFA has simplified the path to 5G private networks and is helping to accelerate the ecosystem.”

To join the MFA, learn more about Uni5G or how to access PLMN ID numbers, or receive notifications on the Uni5G Technology Blueprint, visit www.mfa-tech.org .

Resources:

About the MFA

MFA (MulteFire Alliance) is an international organization that is championing the global industry adoption of private cellular networks using MFA-defined MulteFire specifications for LTE and Uni5G technology blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye